Random integration of conventional gene delivery vectors such as viruses, plasmids, P1 phage-derived artificial chromosomes, bacterial artificial chromosomes and yeast artificial chromosomes can be associated with transgene silencing. Furthermore, integrated viral sequences can activate oncogenes adjacent to the insertion site resulting in cancer. Various human artificial chromosomes (HACs) exhibit several potential characteristics desired for an ideal gene delivery vector, including stable episomal maintenance and the capacity to carry large genomic loci with their regulatory elements, thus allowing the physiological regulation of the introduced gene in a manner similar to that of native chromosomes. HACs have been generated mainly using either a "top-down approach" (engineered chromosomes), or a "bottom-up approach" (de novo artificial chromosomes). The recent emergence of stem cell-based tissue engineering has opened up new avenues for gene and cell therapies. This review describes the lessons learned and prospects identified mainly from studies in the construction of HACs and HAC-mediated gene expression systems in cultured cells, as well as in animals.
INTRODUCTION
Gene therapy has been envisioned to provide a direct and permanent correction of genetic defects. To achieve the desired e ects, therapeutic genes need to be carried by safe and e ective vectors that can deliver foreign genes to speci c cells and therea er sustain their expression in a physiologically regulated fashion. Gene delivery vectors with the following properties may further add to the applications for gene and cell therapies: (i) high transfection e ciency; (ii) long-term stable maintenance in host cells without integration into the host genome; (iii) appropriate levels of spatial and temporal expression of therapeutic genes in speci cally desired cells; and (iv) no risk of cellular transformation or stimulation of the host's immune system. Although a number of di erent approaches have been attempted to achieve e cient gene transfer and long-term gene expression, this challenging task remains unful lled as all current methods have some limitations. For example, adenovirus-derived vectors have been widely employed in many current gene therapies because of their high infectivity in a wide variety of cell types and tissues, independent of the proliferative state.
1,2 However, adenovirus-mediated transgene expression is transient and needs high-titer administration. e consequent toxicity and undesired immunological response make adenovirusbased gene therapies risky. 3 Other popular choices include wellcharacterized retroviral vectors, which enable sustained transgene expression in dividing cells by integration of target genes into the host cell genome. However, retroviruses have been reported to favor integration into sites near transcription start regions of the host genome, thus causing insertional mutagenesis with retrovirus-based vectors. [4] [5] [6] In addition, transcriptional silencing caused by retroviral vector integration is o en observed in mouse stem cells and transfected hematopoietic stem cells. 7, 8 In comparison to the other approaches, lentiviral vectors o er an attractive means of gene delivery because such viruses can transduce dividing and quiescent cells. [9] [10] [11] [12] HIV-based vectors have recently been utilized successfully for human gene correction, although integrations of the vectors into the host genome were observed. 13, 14 Recently, integration-de cient lentiviral vectors were developed through the use of integrase mutations. 12, 15 Integration-de cient lentiviral vectors have a much lower risk of insertional mutagenesis and replication-component recombinant (RCR) generation than integrating lentiviral vectors. Although integration-de cient lentiviral vectors can mediate stable expression in non-dividing cells, integration-de cient lentiviral vectors show transient expression in proliferating cells. An alternative solution to these problems could be the use of human arti cial chromosome (HAC) vectors.
Although the e ciency of transferring the HACs into the recipient cells is lower than that of conventional viral vectors, HACs replicate and segregate as natural chromosomes, independently from the host genome, thus overcoming the problems. [16] [17] [18] [19] [20] [21] [22] is review describes various types of HACs and their potential characteristics. Methods of chromosome transfer, examples of gene delivery including genetic correction, pharmaceutical protein production and animal transgenesis, as well as possible usage for other purposes are also introduced. 
ADVANTAGES OF HAC FOR GENE DELIVERY
Method for constructing HAC vectors and potential characteristics of HACs are described in Figure 1 . HACs are exogenous minichromosomes arti cially created mainly by either a "top-down approach" (engineered chromosomes), or a "bottom-up approach" (de novo arti cial chromosomes). e chromosomes can be transferred into host cells, mainly by microcell-mediated chromosome transfer (MMCT), as described in a following section. HACs can faithfully mimic the normal pattern of gene expression because they can hold complete genomic loci, including upstream and downstream regulatory elements. 22, 23 In addition, because of their episomal nature, many complications, such as silencing of the therapeutic gene or oncogenesis resulting from integration at unfavorable sites, should be minimized. Although there are potential gene silencing problems in several HAC vectors, due to the insertion of the transgenes close to a functional kinetochore consisting a large blocks of heterochromatin that could inactivate the gene, surrounding transgenes with insulators can protect them from the positional e ects of the neighboring sequences at the insertional site of a transferred gene. 24, 25 It might also be possible to maintain long-term correction of defective genes because these vectors are mitotically stable throughout many cell divisions, at least in human cells. Such a capability would be advantageous over current gene delivery methods.
VARIOUS TYPES OF HACs AND EPISOMAL VECTORS
e de novo assembly of HACs using the bottom-up approach was developed in human brosarcoma HT1080 cells. 16, 17, [26] [27] [28] [29] [30] [31] [32] [33] [34] In most cases, de novo-generated HACs range from 1 to 10 Mb in size, and have been shown to be mitotically stable. Recently, other systems for the construction of HACs have been developed to rapidly create bacterial arti cial chromosome (BAC)-based HACs using the redrecombination system from bacteriophage λ, 35 or using a modi ed bacterial Tn5 transposon. 31 Utilization of invasive Escherichia coli systems may facilitate de novo HAC formation. 36 Recently, a technique based on the HSV1 amplicon greatly improved de novo HAC formation protocols (i.e., much higher e ciency and applicability to many di erent cell lines other than HT1080). 37 Conversely, HACs engineered via the top-down approach can also be constructed by telomere-associated chromosome fragmentation techniques in the homologous recombination-procient chicken cell line, DT40. 38 Such an approach can generate mitotically stable, linear mini-chromosomes. Initially, mini-chromosomes ranging in size from 0.5 to 10 Mb have been produced from both the human X [39] [40] [41] and Y chromosomes. [42] [43] [44] [45] [46] ese minichromosomes retain a normal centromere and are mitotically stable in human cells with only minor rearrangements.
ere are other types of gene delivery systems that aim to achieve episomal maintenance and introduction of large sized genomic DNA (>100 kb). 47, 48 ey include utilization of (i) naturally occurring or patient-derived mini-chromosomes, 18, [49] [50] [51] (ii) neocentromere-based mini-chromosomes, 52 (iii) murine satellitebased arti cial chromosomes, [53] [54] [55] and (iv) self-replicating viral vector amplicons. [56] [57] [58] [59] e following sections provide an overview and in depth discussions of the work on HACs with speci ed acceptor sites for delivery of desired gene(s).
HACs with acceptor sites e HACs described above require a cloning site for inserting exogenic genes. Recently, HACs with an acceptor site(s) for gene delivery have been developed and characterized as follows. For example, the 21ΔqHAC and 21ΔpqHAC have been constructed by telomere-directed breakage of a human chromosome 21 (hChr. 21) in DT40 cells via the top-down approach. 21 To construct this HAC vector, substantial segments of both the p-and q-arm of an hChr. 21 were deleted through two rounds of telomere-directed chromosome truncation. Next, a single loxP sequence (a target sequence for homologous recombination by Cre recombinase) with a neo gene lacking a promoter was introduced into a euchromatic region of the remaining q-arm. erefore, at least in theory, any circular DNA (plasmid, BAC, P1 phage-derived articial chromosome, or circular yeast arti cial chromosome) with a loxP site and a promoter can restore the neo gene expression by Cre-mediated insertion at the loxP site of the 21ΔqHAC or 21ΔpqHAC. A summary of HACs with acceptor site(s) and their characteristics are described in Table 1 . Single or multiple cloning site(s), including loxP, FRT, attP and attB, [60] [61] [62] have been inserted into HAC vectors, including de novo-created HACs, engineered HACs, patient-derived chromosomes and natural chromosomal fragments. Several characteristics are needed for HAC vectors to be ideal for human gene and cell therapy, including physiological and functional expression of desired gene(s), independent maintenance of the HACs in the host cells, high mitotic stability of the HACs, at least in human cells, and harmlessness to the host cells or bodies. Since detailed characteristics of the HACs in Table 1 have not been compared among those in published papers, the most feasible HAC is currently uncertain. e recently developed 21HACs (including 21HAC1, 21HAC2, 21HAC3 and 21HAC4) may be very useful tools for human gene and cell therapy, since they exhibit many of the characteristics described above, and gene delivery has been accomplished using these vectors. [63] [64] [65] [66] [67] e next sections mainly describe and discuss two of newly developed HAC vector systems, the 21HACs and tet-O-HAC.
68
Characterization of two novel HAC systems HAC vectors were developed from a normal hChr.14 or hChr.21 using an engineering approach (named SC20-HAC and 21∆qHAC/21∆pqHAC) that incorporates a loxP gene acceptor site. 21, 22 e SC20-HAC was transmittable through the germline and was rather mitotically stable in mice and cattle. 22, [69] [70] [71] Both 21∆qHAC and 21∆pqHAC were very stable, especially when introduced in human cell lines. 21, 24, 72 However, SC20-HAC and 21∆qHAC/21∆pqHAC contain several structurally unde ned regions carrying many endogenous genes, which causes a genetic imbalance in cells propagating these HACs.
is may a ect physiological gene expression patterns, resulting in abnormal development. Although these HACs showed signi cant potential for gene therapy and animal transgenesis, the ideal gene delivery vector should be structurally de ned and should not contain endogenous genes from the original chromosome. us, a novel 21HAC vector was developed without known endogenous genes using the top-down approach 63 ( Figure 2a) . is 21HAC was physically characterized using a transformation-associated recombination-cloning strategy followed by sequencing of transformation-associated recombination-BAC clones, 73 con rming that no known endogenous genes remained in the 21HAC. Although the newer 21HAC could be producing unknown noncoding RNAs of physiological consequence, since non-α satellite-based 21 pericentromeric sequences remain on the 21HAC, any remaining pericentromeric non-α satellite-based sequences from the 21HAC can be removed prior to future clinical application. Since the suicide gene herpes simplex virus thymidine kinase, as a safeguard system against tumor formation, was also inserted into the HAC vector together with a loxP site, tumor cells containing the HAC carrying the suicide gene can be selectively killed by ganciclovir in vitro and in vivo. 63, 65 us, the resulting 21HAC vector contains four useful features: (i) it has a well-de ned genetic architecture; (ii) it is episomally present, independent of the host chromosomes; (iii) it is mitotically stable in human somatic cells in vitro and mouse cells both in vitro and in vivo; and (iv) it has a system for safeguarding against tumor formation. Furthermore, any desired gene could be cloned into the 21HAC using the Cre-loxP system in Chinese hamster ovary cells, or by a homologous recombination system in DT40 cells. 63 Using the homologous recombination system, two di erent vectors, each containing a desired gene, were inserted sequentially into 21HAC1 by homologous recombination in DT40 cells (Figure 2b) . Two or more vectors containing desired genes can be inserted sequentially into the HAC. Using the Cre-loxP system, insertion-type cloning and translocation-type cloning were applied for gene cloning. Circular vectors containing desired genes, such as plasmids, P1 phage-derived arti cial chromosomes and BACs, can be inserted into the HAC vector using insertiontype cloning (Figure 2c) . Mb-sized genes, which cannot be cloned into the circular vectors, can be cloned into the HAC vector using (Figure 2d ). More recently, a HAC vector containing ve recombination platforms (φC31 attP, R4 attP, TP901-1 attP, Bxb1 attP and FRT; multi-integrase-HAC vector) was developed. 67 e insertion frequency of target genes into each platform on multi-integrase-HAC using the de novo mammalian codon-optimized integrases, including φC31, R4, TP901-1 and Bxb1, was much higher than that using FLPe. us, ve different circular vectors, such as plasmids and BACs containing genes of interest, can be cloned into the multi-integrase-HAC vector. erefore, any combination of genes, including full-length genomic DNA, can in theory be cloned into the HAC derivatives by a combination of these cloning systems and transferred into a desired recipient cell type using the HAC (Figure 2e) . us, these novel 21HAC vectors may be useful for gene and cell therapies as well as for animal transgenesis.
Recently, a HAC with a conditional centromere that includes the tetracycline operator (tet-O) sequence embedded in the alphoid DNA array has been generated 74 ( Figure 3a) . is conditional centromere can be inactivated, loss of the alphoid tet-O HAC (tet-O HAC), by expression of tet-repressor fusion proteins. Since the desired gene cannot be inserted into the tet-O HAC without an acceptor site, such as loxP or FRT, the tet-O HAC vector was adapted for gene delivery and gene expression in human cells 68 (Figure 3b) . A loxP cassette was inserted into the tet-O HAC by homologous recombination in chicken DT40 cells following MMCT. e tet-O HAC with the loxP cassette was then transferred into Chinese hamster ovary cells. It has been shown that the enhanced green uorescent protein (EGFP) transgene was e ciently and accurately incorporated into the tet-O HAC vector (Figure 3c ). e EGFP transgene was stably expressed in human cells a er transfer via MMCT, and the transgenes inserted into the tet-O HAC can be subsequently eliminated from cells by HAC loss due to centromere inactivation (Figure 3d ). e tet-O HAC vector has signi cant advantages over other expression/cloning systems, because it provides a mechanism to compare the phenotype of a mammalian cell with or without a functional copy of any cloned gene of interest. us, a rigorous negative control for phenotypic changes attributed to expression of the cloned gene can be conducted easily in any population of dividing cells by simply inactivating the tet-O HAC centromere. Such controls are required for proper interpretation of gene function studies. In addition, the modi ed tet-O HAC vector can be used for experiments that require transient expression of a cloned gene of interest. For example, the generation of induced pluripotent stem (iPS) cells is possible through the transient expression of speci c cellular factors, including OCT4, SOX2, KLF4, cMYC, and LIN28. [75] [76] [77] In this case, HAC elimination and removal of the stem cell-inducing factors could provide a strategy to avoid insertional mutagenesis and cell transformation, complications that are frequently observed during cell reprogramming. Taken together, the natural human centromere sequence with α-satellite is retained on the linear telomere-capped 21HAC (engineered HAC), while the de novo-generated tet-O HAC is formed from transfected α-satellite DNA and is circular. An advantage of 21HAC and tet-O HAC is that they have the ability to control transgene number. us, the combination of the 21HACs and tet-O HAC will be useful tools for human gene and cell therapies, since the 21HACs are persistent in human cells and tet-O HAC is removable from the cells.
CHROMOSOME TRANSFER INTO DESIRED HOST CELLS
e e ciency of chromosome transfer into the desired host cells is crucial when using any of the HACs described above. MMCT is a technique by which a chromosome(s) is moved from donor to recipient cells by microcell fusion. 78, 79 Polyethylene glycol (PEG) has conventionally been used as a fusogen, and has been employed very successfully in various genetic studies. 80 However, PEG is not applicable for all types of recipient cell, due to its celltype-dependent toxicity and low e ciency. Furthermore, PEG produces a low yield of microcell hybrids (10 −6 -10 −5 per recipient cells). Although hemagglutinating virus of JAPAN envelope was utilized for MMCT, the transfer e ciency was approximately three to eight times higher than that of the PEG-mediated MMCT method. 81 To harness the full potential of MMCT, a more e cient, less toxic fusion protocol is needed.
e measles virus (MV), which causes an acute contagious disease, has an envelope protein complex that is used for both virus attachment and membrane fusion. 82 us, the feasibility of using the MV viral fusion machinery was tested as an alternative to PEG for microcell fusion. e introduction of genes encoding MV envelope proteins enabled rodent cells to produce fusogenic microcells that e ciently transmit donor chromosomes to recipient human cells expressing a high level of CD46. 83 e maximum e ciency observed was 50 and 100 times greater than that using conventional PEG fusion. is MV-mediated MMCT method has several advantages over the conventional PEG-fusion method for chromosome transfer. First, microcell hybrids can be obtained from a low number of recipients, even from recipients that are too low in number for hybrids to be obtained by PEG-fusion, as long as the recipients express the CD46 receptor over a threshold density. Second, the procedure for microcell fusion is simple. e formation of microcell hybrids requires only the addition of prepared microcells to recipient cells. is ease of application, which avoids the laborious tasks of handling a highly viscous PEG solution and performing repeated washout steps, should improve the reproducibility of microcell fusion. e next issue for microcell fusion via an MV fusogen is whether the tropism for recipient cells can be altered from the default CD46 receptor to arbitrary receptors. Since engineering of viral tropism has been pursued for many gene therapy-based strategies, [84] [85] [86] [87] [88] [89] [90] the modi cation of the viral tropism potentially enables retargeting of fusogenic microcells, not only to recipient cells of interest in vitro, but also to desired cells in vivo.
Using the MMCT technique, HACs cannot be directly transferred to recipient cells from donor cells that cannot form microcells. Recently, Ikeno and colleagues established an alternative transfer technology for the isolation and transfection of HACs into target cell lines. 91 ey isolated HACs from metaphase cells using a simple 25% sucrose cushion centrifugation under polyamine bu er conditions. Transfer of HACs into target cell lines was achieved using conventional transfection reagents, which enabled direct transfer of the HAC from a variety of donor cells, including those that could not form microcells. e e ciency of chromosome transfer was comparable to PEG fusion in MMCT.
In contrast, ow-sorted chromosome transfer is a modi ed method based on the isolation of the target chromosome from the host cells by ow sorting. 92 During ow-sorted chromosome transfer, donor cells are rst treated with iodo-deoxyuridine and subsequently blocked at mitotic metaphase by treatment with colchicine. ese chromosomes are then stained with Hoechst 33258 and chromomycin A3, then harvested and puri ed from the background of host chromosomes. e e ciency of chromosome transfer using chromosome transfection and ow-sorted chromosome transfer are comparable to the normal MMCT method (10 ). 93 Both MMCT and alternative HAC transfer protocols require improvement for higher e ciency.
GENES IN HACs
e genes previously loaded on HAC vectors are listed in Table 2 . Several studies have demonstrated the feasibility of de novo HAC construction for the delivery and expression of large human transgenes into human cell lines. e successful functional complementation of the hypoxanthine-guaninephosphoribosyltransferase (HPRT) gene has been observed in HPRT-de cient human cells. 19, 35, 37, 72, 94 HPRT was utilized as a model gene for genetic complementation because it is easy to assay functional complementation of metabolic de ciencies in host cells by enumerating hypoxanthine-aminopterin-thymidine-resistant and 6-thioguanine-susceptible colonies. Although several entire human genomic DNA segments related to recessive hereditary disorders, including CFTR, [95] [96] [97] β-globin 34, 91, 98 and Factor IX, 99 were successfully loaded into HACs, most of the studies simply showed the cloning and expression in nona ected cell lines, such as HT1080 and Chinese hamster ovary. However, HACs containing genetic disorder-related genes will be useful tools for future treatment of their disorders. Ito et al. reported the treatment of nonalbumin rats by transplantation of immortalized hepatocytes using a de novo HAC with the SV40T antigen. 100, 101 Although several groups have reported functional analyses in vitro using de novo HACs, several factors limit the application of de novo-generated HACs as gene delivery vehicles. e most critical problems are their unde ned structure and the unpredictable relationship between the input DNA and resultant HAC, especially in terms of their size and composition. 47 is is due to de novo-generated HACs being composed of multimers of the original yeast arti cial chromosome or BAC sequences used for transfection. On the other hand, the apparent formation of de novo-generated HACs from introduced DNA alone may be a favorable safety feature, although the structure should be de ned before clinical use.
Several studies using the 21Δq HAC or 21Δpq HAC vectors have been published, including studies that report the following: (i) the persistent expression of the erythropoietin gene in normal human broblasts; 102 (ii) the tetracycline-inducible expression of the DNA-Pkcs gene; 103 (iii) the induction of tissue-speci c expression of an EGFP reporter gene accompanying in vitro differentiation in human mesenchymal stem cells; 24 (iv) a transformation-associated recombination-cloning mediated gene-cloning system; 104 (v) exogenous gene expression and antigen-mediated growth regulation of human hematopoietic cells; 105 (vi) heat-regulated production and secretion of insulin; 106 (vii) antigen-mediated growth control of hybridoma cells; 107 (viii) cell-type-speci c gene expression and induction of immunoglobin secretion; 108 (ix) telomerase-mediated life-span extension of human primary broblasts; 109 (x) an evaluation system for bioactive substances; 110 and (xi) a ready-made P1 phage-derived arti cial chromosome insertion and correction of a genetic de ciency in multipotent germline stem cells. 72 Recent studies for the treatment of a genetic disease, Duchenne muscular dystrophy (DMD) using the newly developed 21HAC2 has been reported. 66 DMD is caused by dysfunction of the dystrophin gene. 111 As some DMD patients show a large deletion in the DMD gene, these defects cannot be restored by exon-skipping approaches. 112 Although several vectors have been developed for DMD gene therapy, no episomal vector containing the entire dystrophin genomic region has been reported, due to the extremely large size of this region (2.4 Mb). 113 us, a 21HAC2 vector containing the entire dystrophin genomic region (DYS-HAC) has been developed for potential application in DMD gene therapy. 64 iPS cells have great potential for gene therapy, as such cells can be generated from an individual's own tissues, and when reintroduced can contribute to the specialized function of any tissue. [75] [76] [77] As a proof of concept, the complete correction of a genetic deciency was shown in iPS cells derived from DMD model (mdx) mice and a human DMD patient using the DYS-HAC. 66 Advances in the e ciency of methods used for di erentiation and puri cation of stem cells, including embryonic stem (ES) and iPS cells, are anticipated, and the application of these methods to ES/iPS cells combined with HAC vector systems may enable the development of more sophisticated gene therapies. us, stem cells, potentially derived from multiple sources, combined with HAC-mediated gene delivery should permit safe treatment of various genetic defects. e next step in the future of gene therapy is to demonstrate functional restoration in vivo using animal models.
ANIMAL MODELS
Another important application of HACs or hCFs (human chromosome fragments) is animal transgenesis. e ability of hCFs to act as vectors for introducing large stretches of human DNA into mice was rst demonstrated in 1997. 23 An hCF containing the human immunoglobulin gene locus was introduced into mouse ES cells, followed by the production of chimeric mice. Transferred hCFs were stably maintained as an extra chromosome in the somatic cells of mice and their human genes were expressed under proper tissue-speci c regulation. In some cases they could be transmitted through the germline, resulting in the establishment of novel mouse strains (transchromosomic mice) containing a heritable hCF. 23 erefore, employing chromosome vectors to create transgenic animals is useful for overcoming the size constraints of cloned transgenes used in conventional techniques, and to facilitate functional studies of the human genome. However, it has been reported that the mitotic stability of hCFs in mice varies among chromosomes. 69, 70 us, it is di cult to stably maintain certain types of hCFs in order to perform functional analyses of several chromosomes in mice. Furthermore, it has proven to be di cult to introduce de ned regions of hCFs into mice because fragmentation of hCFs can occur randomly. us, Kuroiwa and colleagues developed a chromosome-cloning system in which de ned regions of human chromosomes can be cloned into a mitotically stable human mini-chromosome vector (hChr.14-derived SC20-HAC) in homologous recombination-pro cient chicken DT40 cells. 22 e stable SC20-HAC vector allowed a 10 Mb-sized region of the mitotically unstable human chromosome 22 to be stably maintained in mouse ES cells, as well as in mice. Furthermore, they demonstrated functional expression of human genes in mice with this construct. is study clearly demonstrated the possibility of expressing human antibodies in mice. is technology was also applied to cows with nuclear transfer of the broblasts containing the HAC. 71, 114 Furthermore, to generate humanized CYP3A mice for prediction of human xenobiotic metabolism, the region around the CYP3A cluster (~700 kb) in hChr. 7 was cloned into the SC20-HAC vector. Germline-transmittable CYP3A-HAC mice were generated that exhibited CYP3A gene expression in a tissue-and developmentally speci c manner (Y. Kazuki, K. Kobayashi, T. Oshima, S. Aueviriyavit, S. Abe, M. Takiguchi et al. unpublished results). Furthermore, this strategy, using a chromosome-cloning system, was also utilized in constructing a HAC containing the entire 2.4 Mb human dystrophin gene described above. 64 e availability of HAC vectors would be of great value in the construction of animals carrying human genetic elements to model speci c diseases, or in the commercial production of various therapeutic/other products.
Another application of chromosome engineering technology is to generate animal models of human aneuploidy syndromes, which are caused by extra dosage of wild-type genes on human chromosomes. Trisomy of chromosome 21 is the most common live-born human aneuploidy and results in a constellation of features known as Down syndrome. 115 Two groups have successfully generated transchromosomic Down syndrome model mice. 116, 117 ese mice contain an extra hChr. 21 and show cardiac abnormalities and behavioral impairment similar to patients with Down syndrome. e critical di erence between the two studies was the region of the hChr. 21 transmitted through the germline. Fisher's group succeeded in generating an aneuploid mouse that stably transmits a freely segregating, almost complete hChr. 21 through the germline. 117 On the other hand, Oshimura's group generated germline-transmittable mice containing a partial fragment of hChr. 21. 118 Transchromosomic mouse technology can be useful in the dissection of other human aneuploidies as well as to identify and map genes that contribute to aneuploidy diseases.
POSSIBLE USAGE FOR OTHER PURPOSES
Several properties of HACs enable their potential use in a variety of applications. HACs could increase protein production e ciency since a HAC can be loaded with multiple copies of a particular gene. Most recently, we have compared the expression levels of HAC-derived transgene products with a transfected P1 phage-derived arti cial chromosome containing the same gene.
e former showed expression levels consistent with those of the original clones, even a er 50 population doublings, whereas the latter showed a remarkable decrease in expression despite unvarying DNA content, indicating that the gene on the HAC is resistant to gene silencing (H. Kurosaki, M. Hiratsuka, N. Imaoka, Y. Iida, N. Uno, Y. Kazuki et al., unpublished results). e ability to insert di erent transgenes at multiple locations in the HAC, using sitespeci c recombinases, such as φC31, R4, TP901-1 and Bxb1, may also have bene ts for screening the interaction of gene products. 67 Most recently, several research groups have developed a technology to induce ES-like stem cells, so-called iPS cells, from mouse and human broblasts. [75] [76] [77] A HAC vector containing the four initiation factors (Oct4, Sox2, c-Myc, and Klf4) and others that enhance pluripotency might be suitable for the development of iPS cells. As stated earlier, a HAC carrying herpes simplex virus thymidine kinase and other suicide genes with proper promoters may be useful in preventing tumor formation. us, HACs may prove to be powerful tools for the generation of iPS cells ideal for gene and cell therapies because of the following advantages: (i) e cient generation of iPS cells; (ii) no integration of the transgene into the host genome; (iii) e cient di erentiation from iPS cells; (iv) e cient puri cation of di erentiated cells; and (v) safeguarding against tumor formation.
CONCLUSIONS AND PERSPECTIVES
e chromosome vector systems o er complementary and desirable characteristics for use as gene delivery vectors to overcome various problems in existing viral and nonviral vector systems. HACs also have the advantages of being mitotically stable in the absence of selection and they have an inde nite cloning capacity, thus allowing for the insertion of all control elements for the correct expression of the transgene. A schematic diagram of the potential usage of the HAC vector system for functional analyses and for the treatment of genetic disorders is described in Figure 4 . A feasible therapeutic application of HAC vectors would be the ex vivo transduction of a gene of interest by the transfer of a HAC into stem cells followed by autologous transplantation. Stem cells possess two characteristic features: the ability for self-renewal, and the ability for multilineage di erentiation. In addition, stem cells, including hematopoietic stem cells, 119, 120 bone marrow-derived mesenchymal stem cells, 24 mesoangioblasts, 121 multipotent germline stem cells 122 and iPS cells, [75] [76] [77] can potentially avoid immune rejection due to their being obtained from the patient's own tissues, although stem cell-based therapies (with the exception of hematopoietic stem cells) are still in their infancy. Most recently, neurons, cardiomyocytes and blood progenitors were induced by de ned factors from normal broblasts via a direct reprogramming (or direct conversion) approach. [123] [124] [125] us, genetically corrected broblasts may be useful not only for the iPS production but also for the direct conversion to speci c di erentiated cells.
e potential utility of HACs to correct a genetic defect has been demonstrated in cultured cells and animal models. However, prior to the use of HAC vectors in the clinical treatment of patients, their e cacy and safety as a treatment modality should be evaluated in animal models. Future research will focus on the e cient delivery of such vectors, not only to cells cultured in vitro but also to animal cells in vivo. Taken together, the various HAC vectors developed by several groups will be useful for designing HAC-based gene and cell therapies, as well as for the generation of humanized animal models. us, HACs may be designated as "multipotent vectors". Several approaches including ex vivo or in vivo therapies will be potentially utilized in the treatment of genetic diseases. For example, naked HACs or microcells with the HAC containing therapeutic gene(s) are directly injected to patient's tissues. HSC, hematopoietic stem cell; iPS, induced pluripotent stem; MAB, mesoangioblast; mGS, multipotent germline stem; MSC, mesenchymal stem cell.
